R&D projects

INDEVION Biotech Ltd. has several ongoing and successfully closed projects targeting cutting-edge solution and proprietary technology development, and novel recombinant products in the field of CELL/GENOME ENGINEERING, BIONANOTECHNOLOGY, ORIGINAL AND BIOSIMILAR DRUG DEVELOPMENT, EPIGENETICS, ANTIBODY AND CYTOKINE ENGINEERING AND DEVELOPMENT, THERAPEUTIC ANTIBODY GLYCOSYLATION ANALYSIS AND QUALITY CONTROL …

CELL/GENOME ENGINEERING

Recent specific genome editing technologies allow us to precisely position deletions, modifications, and transgenes in the genomes of living cells. As a result, stable cell lines can be generated with controlled characteristics and predictable transgene functioning for the purpose of e.g. fundamental research, bioassays, and recombinant protein production.

Specific genome editing technologies are still in the initial evolutionary phase (it is true especially for TAL effector nucleases and some upcoming new approaches), that means, besides the substantial optimisation work one need to carry out, one also has to innovate a lot in the adaptation of the commercially available systems (e.g. Cellectis Bioresearch or currently the System Biology Division of Life Technologies) to the specific applications.

Therefore, and as a result, while going along our genome editing routes, we were  forced to implement and developed new technologies (i) to assess genome modifications at early stages of TALEN transfections, based on specific amlification and capture of modified sequences for more accurate quantification and sequencing, (ii) generally applicable strategies and tools for the detection of, and direct enrichment for assisted KO cells using e.g. flow cytometry, and (iii) new approaches to map TALEN specificity in vivo in automated and HTS assays. Most promisingly, we are keen (iv) to device and test some new/proprietary genome editing approaches, which are completely divergent from the current state of the art. LINK

BIONANOTECHNOLOGY

Biopolymer-based nanoparticle system for the encapsulation and targeted delivery of pharmaceuticals (BBS NanoTech)

Patent Application: Borbély, J., Bodnár, M., Hajdu, I., Hartmann, J.F., Keresztessy, Z., Nagy, L., Vamosi, G. Polymeric Nanoparticles by Ion-Ion Interactions. US Utility Patent Application No. US 60/833,672. PCT Patent Application No. WO/2009/035438.LINK

ORIGINAL AND BIOSIMILAR DRUG DEVELOPMENT

REPORTER AND EFFECTOR BIOASSAY CELL LINES (UDG)

- stable/genome engineered custom cell lines expressing cell surface markers suitable for complex bioassays in

- biosimilar development and production QC

- to support FDA & EMEA approval  of biosimilars via the in vitro studies

PRODUCER CELL LINES (UDG)

- stable/genome engineered cell lines (HEK/CHO) expressing at high levels of recombinant proteins (industrial scale)

- for biosimilar production

- for recombinant protein production

BIOASSAYS – for biosimilar development and production QC (UDG)

EPIGENETICS

Epigenetics technology standardisation for clinical diagnostics –ChIP  process controls (GENOMICS).

Patent Application: Balint, B.L., Nagy, L., Keresztessy, Z, Zahuczky, G. Control System for Immunoprecipitation Studies. US Utility Patent Application No. US 61/666,945, Hungarian Registry No. 1222304, PCT submitted 06.2013

ANTIBODY AND CYTOKINE ENGINEERING AND DEVELOPMENT

Development of monoclonal antibodies for ChIP applications (PROXENCELL)

Cytokine production development in mammalian cells (PROXENCELL)

THERAPEUTIC ANTIBODY GLYCOSYLATION ANALYSIS AND QUALITY CONTROL

Development of glycane sequencing kit solution and production of recombinant enzymes (HLBS)

Please, visit project lists at the Competencies page.

 

For more information, please, contact us at: info@indevion.eu